What Gelomics does

Gelomics is an Australian biotechnology company headquartered in Kelvin Grove, Brisbane (Queensland), founded in 2018 around photopolymerizable gelatin methacryloyl (GelMA) hydrogel technology developed at Queensland University of Technology. The company builds 3D tissue culture systems for preclinical drug discovery, disease modeling, and translational research, with core offerings spanning the LunaX Mechanistic 3D Tissue Culture Platform, the LunaX Crosslinker (a 405nm visible-light photocrosslinking device that forms hydrogels in under 15 minutes), the patent-pending CytoX LED technology for individual per-well stiffness control, and 20+ ready-to-use LunaX ECM formulations including LunaGel Ultrapure GelMA (developed with Rousselot X-Pure technology at <10 EU/g endotoxin). The product portfolio is complemented by the NovaX automation-ready platform for high-throughput compound screening and a contract research services arm covering oncology, immuno-oncology, toxicology, and custom assay development.

Gelomics generates revenue through three streams: consumables and hardware sales (LunaGel ECM kits, LunaCrosslinker and LunaX Crosslinker devices), contract research services for pharmaceutical and biotech clients, and a subscription-style LunaX Early Access Program (3-month+ access with bundled discounts and applications support). Pricing is quote-based and not publicly disclosed; a 4-week free trial of the LunaCrosslinker supports hardware demand generation. Go-to-market combines direct enterprise field sales, a Scientist.com marketplace listing for US pharmaceutical access, and exclusive regional distribution partnerships across 23+ international markets, with named distributors covering Nordics/Baltics (BioNordika), Benelux (Morpho Biotech), France/Italy (Eurobio Scientific), Italy (Voden Medical), Switzerland (Bucher Biotec), UK/Ireland (Scientific Laboratory Supplies), Japan (Kiko Tech), and South Korea (MediPL Bio-labs).

Target customers include academic researchers (logos include Harvard, Imperial College London, University of Queensland, Monash, QUT, TU Munich, and others), pharmaceutical companies seeking predictive preclinical models to reduce late-stage drug failure, and contract research organizations requiring validated 3D culture platforms. The company has raised over USD 12 million in R&D and venture capital since 2017, plus AUD 948,066 in non-dilutive government grant funding in June 2025, and operates from a Triple ISO-certified facility (ISO 9001, ISO 14001, ISO 45001) with a Scientific Advisory Board featuring globally cited researchers including Professor Dame Molly Stevens and Distinguished Professors Dietmar Hutmacher, Travis Klein, and Gail Risbridger.

Name

Gelomics

Legal name

Gelomics Pty Ltd

Website

https://gelomics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Gelomics is an Australian biotechnology company that develops visible-light photocrosslinking hardware and GelMA hydrogel consumables for 3D tissue culture, serving academic researchers, pharmaceutical companies, and CROs in preclinical drug discovery.

Ownership category

akta.pro rank

Product category

3D Cell Culture Reagents and Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)

SIC

Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• 3D cell culture
• Tissue engineering hydrogels
• Photocrosslinkable biomaterials
• Preclinical drug discovery
• Extracellular matrix products

Headquarters

HQ city

Kelvin Grove

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Consumables & Hardware): Sale of LunaGel™ hydrogels (ECM kits), LunaX™ Crosslinker hardware, and LunaCrosslinker™ devices. Consumables include various ECM formulations at different stiffness levels. Hardware includes photocrosslinking equipment for 3D tissue culture.
2. Contract Research Services (CRO): Fee-for-service preclinical research including bioassays, disease models, assay validation, high-throughput screening, mechanistic studies, immuno-oncology assays, and AI-powered data analysis. Project-based engagements from consultation through reporting.
3. LunaX™ Early Access Program: 3-month+ early access program offering LunaX platform access, 20% discount on ECM kits during trial, expert applications support, and optional co-authorship opportunities on whitepapers or case studies.

Pricing tiers

Go-to-market motion5 records

Distribution channels12 records

Marketing channels11 records

Core offering

Gelomics develops and sells a 3D tissue culture platform (LunaX™) that combines photocrosslinking hardware (LunaX Crosslinker with 405nm visible light LEDs and patent-pending CytoX™ LED per-well crosslinking), a portfolio of 20+ ready-to-use GelMA-based extracellular matrix (ECM) hydrogel kits (LunaGel™), and the LunaX™ Cloud AI engine for predictive data analysis. The company also offers contract research services spanning oncology, immuno-oncology, toxicology, and disease modeling using 3D tissue models. Customers include academic researchers, pharmaceutical companies, and CROs working on preclinical drug discovery and disease modeling.

Product overview

Gelomics offers the LunaX Mechanistic 3D Tissue Culture Platform as its core technology, comprising the LunaX Crosslinker hardware with patent-pending CytoX LED individual-well crosslinking capability, 20+ LunaX ECM formulations, and the LunaX Cloud AI-powered data analysis engine. Complementary to this is the LunaGel product line including LunaGel Ultrapure GelMA ECM (developed with Rousselot X-Pure technology) and Lamina 3D hydrogels. The platform is complemented by the automation-ready NovaX high-throughput screening platform and a full suite of contract research services spanning bioassays, disease models, assay development, and AI-powered data analysis for preclinical drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• LunaX™: AI-powered Mechanistic 3D Tissue Culture Platform featuring Crosslinker, Cloud, and CytoX™ LED technology for advanced 3D cell culture
• LunaGel™
• CytoX™ LED
• LunaXCloud™
• NovaX™
• Lamina 3D™

Products and services

• LunaX™ Mechanistic 3D Tissue Culture Platform Core integrated platform combining photocrosslinking hardware (LunaX Crosslinker with 405nm visible light LEDs), 20+ ECM hydrogel formulations, and the LunaX Cloud AI analysis engine, enabling researchers to create physiologically relevant 3D tissue models in under 15 minutes with tunable matrix stiffness control for disease modeling and drug discovery.
• LunaX™ Crosslinker Photocrosslinking hardware device equipped with 405nm high-power LEDs that enables ultrafast hydrogel formation in under 15 minutes while protecting cell viability. Features the patent-pending CytoX™ LED technology allowing individual sample crosslinking and precise per-well ECM stiffness tuning for disease-specific tissue models.
• LunaX™ ECM Formulations Portfolio of 20+ ready-to-use GelMA-based extracellular matrix hydrogel kits engineered for control, consistency, ease-of-use, and compatibility with the LunaX Crosslinker system. Includes High Stiffness and Low Stiffness variants to mimic healthy or diseased tissue environments for drug discovery and disease modeling.
• LunaGel™ Ultrapure GelMA ECM Highly purified photocrosslinkable extracellular matrix based on Rousselot X-Pure GelMA technology, offering ultra-low endotoxin levels (<10 EU/g), precise control over matrix porosity and stiffness, optically transparent hydrogels, and superior batch-to-batch consistency for sensitive 3D cell culture applications and translational research.
• LunaCrosslinker™ Photocrosslinking device available through a 4-week free trial program, allowing researchers to evaluate Gelomics' visible light crosslinking hardware for 3D tissue culture before purchase. Covered by 12-month warranty with option for extended warranty.
• NovaX™ Platform Automation-ready high-throughput screening platform enabling rapid screening of compound libraries for efficacy and toxicity in highly reproducible 3D human-relevant models. Designed for automated preclinical drug screening workflows.
• Lamina 3D™ Hydrogels Advanced 3D cell culture hydrogels distributed alongside LunaGel products in select markets (e.g., Benelux region), supporting the creation of complex, reproducible, cost-effective, and scalable human tissue models.
• 3D Disease Models & Bioassays (Contract Research Services) Expert-led fee-for-service contract research covering oncology and tumor microenvironment models (tumor spheroids, tumor-stroma co-cultures, patient-derived organoids, metastasis models), immuno-oncology assays (immune-tumor co-cultures, checkpoint inhibitor evaluation, T-cell engager models), toxicology and safety testing (liver spheroids, cardiac organoids, nephrotoxicity models), and mechanistic studies (angiogenesis, fibrosis, BBB models). Project-based engagements from consultation through reporting for biotech and pharma clients.
• Custom 3D Assay Development Services Bespoke assay design and development services for custom 3D cell culture models (spheroids, organoids, co-cultures) tailored to specific drug targets, cell types, or disease states, including assay validation and optimization for pharma and biotech clients.
• AI-Powered Data Analysis Services Predictive modeling, IC50 calculations, toxicology profiling, and in-silico optimization services powered by the LunaXCloud AI engine, providing comprehensive data science support for preclinical drug discovery and 3D tissue culture workflows.

Quantifiable outcome

• Create 3D cell cultures in minutes — no prior experience required
• +4 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core.

• Morpho BiotechcoreChannel Partner/ Reseller/ Distributor · 1 July 2025Morpho Biotech serves as exclusive distributor in Benelux (Netherlands, Belgium, Luxembourg) starting July 1, 2025. Trusted name in life sciences sector known for scientific expertise and strong support network across the region.
• BioNordika GroupcoreChannel Partner/ Reseller/ Distributor · 22 May 2025BioNordika is a trusted distributor representing world-leading life science suppliers with comprehensive workflow solutions in immunology, diagnostics, and molecular biology. Expanded Gelomics presence across Nordic and Baltic regions.
• Distinguished Professor Gail RisbridgercoreStrategic or Co-development Partner · 20 May 2025Scientific Advisory Board member. Distinguished Professor at Monash University, globally renowned leader in men's health, urology, and translational oncology. Shaped Australian National Men's Health Policy. Member of Order of Australia (AM) 2023.
• Scientific Laboratory Supplies (SLS)coreChannel Partner/ Reseller/ Distributor · 15 May 2025SLS serves as exclusive distributor in UK and Ireland. Founded in Nottingham, SLS is UK's largest independent supplier of laboratory products with strong presence in universities, research institutes, biotech, and pharma. Provides expert technical support and tailored solutions for the region.
• Scientist.comcoreChannel Partner/ Reseller/ Distributor · 3 April 2025Marketplace listing providing streamlined access to pharmaceutical and biotech sectors in US. Scientist.com is a trusted supplier for pharmaceutical and biotech sectors since 2007, offering simple, fast, and reliable access to Gelomics products.
• Bucher Biotec AGcoreChannel Partner/ Reseller/ Distributor · 9 January 2025Bucher Biotec serves as exclusive distributor in Switzerland and Liechtenstein. Leading provider of advanced life science solutions with over 45 years of experience delivering high-quality solutions to Swiss researchers, healthcare professionals, and institutions.
• Voden MedicalcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Voden Medical serves as exclusive distributor in Italian market effective January 2025. Leading provider of diagnostic and life science solutions in Italy specializing in cutting-edge technologies supporting healthcare and research communities.
• Rousselot BiomedicalcoreTechnology or Integration · 17 October 2024Partnership for LunaGel™ Ultrapure GelMA ECM using Rousselot's X-Pure® GelMA technology. X-Pure® provides ultra-low impurity levels (Lipopolysaccharide content: <10 EU/g) and excellent batch-to-batch consistency.
• Distinguished Professor Dietmar W. HutmachercoreStrategic or Co-development Partner · 17 October 2024Co-founder and Scientific Advisory Board member. Director of Max Planck Queensland Centre for Materials Science of Extracellular Matrices. Globally recognized leader in tissue engineering and regenerative medicine with 500+ journal articles, h-index 133, 75,000+ citations.
• Professor Travis J. KleincoreStrategic or Co-development Partner · 17 October 2024Co-founder and Scientific Advisory Board member. Distinguished figure in biomedical engineering at QUT leading Cartilage Regeneration Laboratory. 10,000+ citations with senior QUT leadership experience.
• Professor Dame Molly StevenscoreStrategic or Co-development Partner · 17 October 2024Scientific Advisory Board member. John Black Professor of Bionanoscience at Oxford University, Deputy Director of Kavli Institute for Nanoscience Discovery. 400+ papers, 40+ awards including 2023 Novo Nordisk Award. Four spin-out companies.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• InSphero: InSphero is a Swiss-based provider of 3D organoid and spheroid platforms for preclinical drug discovery and toxicity testing. It directly competes with Gelomics in pharma-facing 3D disease modeling services and consumables, targeting the same pharma and CRO customers seeking human-relevant alternatives to 2D culture.
• CN Bio: CN Bio develops organ-on-chip and microphysiological systems for preclinical drug development, including lung and liver models sold to pharma. It is a direct peer to Gelomics' 3D disease model and contract research services business, competing for similar pharma screening budgets.
• BICO (CELLINK): BICO owns CELLINK and other 3D bioprinting and cell culture consumables brands offering hydrogels, bioinks, and bioprinters to academic and pharma customers. It is a direct competitor in the 3D cell culture consumables and hardware category Gelomics targets with LunaGel and LunaX.
• Mimetas: Mimetas is a Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models used in drug discovery. It overlaps directly with Gelomics' LunaGel/LunaX disease modeling and pharma CRO offerings, with a similar customer base of large pharma screening groups.

Broad incumbents

• Lonza: Lonza is a global contract manufacturing and cell culture products provider offering media, primary cells, and bioprocessing solutions to pharma. Its broader portfolio includes 3D culture-adjacent offerings and it represents the type of strategic account Gelomics must win to scale its pharma CRO and consumables business.
• Corning Life Sciences: Corning Life Sciences is the dominant supplier of Matrigel basement membrane extract and other 3D cell culture matrices used in academic and pharma workflows. It is the incumbent Gelomics must displace in nearly every LunaGel engagement, making it the most strategically relevant competitive reference point despite being a much larger, diversified business.
• Sartorius: Sartorius is a major bioprocessing and lab equipment supplier offering cell culture media, bioreactors, and analytical instruments to pharma and biotech. While not focused on photocrosslinking hydrogels, its scale, customer relationships, and consumables catalog make it the broad incumbent against which Gelomics' enterprise pharma ambitions will be measured.

Emerging players

• Organoid Intelligence: Organoid Intelligence (and adjacent organoid platform providers) focuses on AI-enabled organoid and patient-derived model workflows for drug discovery. It is an emerging peer where Gelomics' LunaX Cloud + 3D tissue platform intersects with the AI-driven organoid analysis space.
• Xylyx Bio: Xylyx Bio provides tissue-specific extracellular matrix (ECM) products for physiologically relevant in vitro cell culture. It is a niche emerging peer whose ECM-centric offering overlaps with Gelomics' LunaGel portfolio for customers seeking defined, animal-free 3D matrices.
• Lena Biosciences: Lena Biosciences develops 3D tissue models and scaffolds for drug discovery and tissue engineering applications. As a smaller emerging player, it competes for the same academic and translational research customers evaluating photocrosslinkable and biomimetic 3D culture alternatives to Matrigel.

Market position

Strengths1 record

Weaknesses6 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Gelomics
• LinkedInlinkedin.com/company/gelomics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gelomics